Company: DVAX
Filing Date: 2025-04-17
Form Type: PRRN14A
Source: 0001193125-25-084044
Chunk: 39

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-17
Form: PRRN14A
Chunk 39
---
 in securities. Deep Track Fund is also the Record Stockholder.

DAVID KROIN

David Kroin’s principal business address is 200 Greenwich Avenue, 3 Floor,
Greenwich, Connecticut 06830. Mr. Kroin is a United States citizen. The principal occupation of Mr. Kroin isas an investor and to serve as managing member of the general partner of Deep Track Capital.

BRETT A. ERKMAN

Brett Erkman’s
principal business address is 200 Greenwich Avenue, 3 Floor, Greenwich, Connecticut 06830. Mr. Erkman is a United States citizen. The principal occupation of Mr. Erkman is Managing
Director of Deep Track Capital.

JEFFREY S. FARROW

Jeffrey Farrow’s principal business address is 15440 Laguna Canyon Road, Ste 160, Irvine, California 92618. Mr. Farrow is a United
States citizen. The principal occupation of Mr. Farrow is Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc.

A-1

MICHAEL MULLETTE

Michael Mullette’s principal business address is 3141 Stevens Creek Boulevard, Ste 40547, Sand Jose, California 95117. Mr. Mullette
is a United States citizen. The principal occupation of Mr. Mullette is Interim Chief Executive Officer and Chief Operating Officer of Lykos Therapeutics PBC.

DONALD J. SANTEL

Donald Santel’s
principal business address is 4362 24 Street, San Francisco, CA 94114. Mr. Santel is a United States citizen. The principal occupation of Mr. Santel is serving as Chairman of the Board
of Directors of Tentarix Biotherapeutics, Inc.

A-2

SCHEDULE I TRANSACTIONS IN SECURITIES OF THE COMPANY DURING THE PAST TWO YEARS DEEP TRACK BIOTECHNOLOGY MASTER FUND, LTD.

| Nature of                
 Transaction              |     | Shares of Common Stock 
 Purchased / (Sold)     |              |     | Date of Purchase / 
 Sale               |         |
| Purchase of Common Stock |     |                        |  19,581.0000 |     |                    | 2/13/23 |
| Purchase of Common Stock |     |                        |  23,632.0000 |     |                    | 2/13/23 |
| Purchase of Common Stock |     |                        |  81,327